Transaction details
Paramjeet K. Randhawa, a director at Hercules Capital, Inc. (NASDAQ:HTGC), purchased 3,050 shares of the company’s common stock on March 4, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were acquired at $14.78 apiece, for a total transaction value of $45,079. The Form 4 indicates the transaction was executed as part of the company’s dividend reinvestment plan.
The filing records that, after the purchase, Randhawa directly owns 19,560 shares of Hercules Capital. The Form 4 was signed by Attorney-in-Fact Kiersten Zaza Botelho on March 5, 2026.
Market snapshot cited in the filing
At the time of reporting, HTGC shares were trading at $15.11, with a price-to-earnings ratio of 8.08. Data cited from InvestingPro in the filing shows a dividend yield of 12.44% for the company and notes that Hercules Capital has paid dividends for 22 consecutive years.
Company disclosures and recent corporate developments
Hercules Capital issued preliminary fourth-quarter and year-end estimates that project an increase in net asset value (NAV) per share to a range of $12.10 to $12.16 as of December 31, 2025. That range represents a quarter-on-quarter rise of $0.05 to $0.11 per share compared with the prior quarter, according to the company’s estimate.
Separately, the company amended a loan agreement with Savara Inc., providing contingent access to up to an additional $75 million of funding, subject to U.S. Food and Drug Administration approval of Savara’s investigational therapy.
Analyst action and short report
Piper Sandler lowered its rating on Hercules Capital from Overweight to Neutral, citing the company’s 35% exposure to the software sector and potential risks from disruption related to artificial intelligence. Along with the downgrade, Piper Sandler reduced its price target on the stock from $20.50 to $17.50.
Hunterbrook released a short report raising concerns about Hercules Capital’s valuations on software-related debt and the sustainability of its dividend. The report highlighted that 35% of the firm’s loan portfolio is exposed to software debt. Hunterbrook disclosed that it holds a short position in Hercules Capital while maintaining a long position in a basket of comparable securities.
What the filing shows and what it leaves open
The Form 4 provides a clear record of the director-level purchase and the resulting ownership tally. It also places the transaction alongside several company-level developments and market commentary. The filing does not offer additional commentary from the director on motives or planned future transactions, nor does it provide further detail on the timeline or structure of the Savara funding beyond the FDA-contingent $75 million amendment.
Summary takeaway
A director-level purchase of 3,050 shares at $14.78 each increases Paramjeet K. Randhawa’s direct holding to 19,560 shares. The purchase was processed through the dividend reinvestment plan and signed off by an attorney-in-fact the following day. The transaction occurs amid modest NAV improvement guidance from the company, a conditional funding amendment with Savara Inc., an analyst downgrade tied to software-concentration risk, and a short report flagging valuation and dividend sustainability concerns related to software loan exposure.